Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Scientists have developed a novel Cr-based single-atom catalyst that enables highly efficient hydrogen peroxide (H2O2) production in acidic environments through an electrochemical process. This ...